For Investors
Back More Than a Fund
Before It’s Obvious
Every major investment category looks inevitable in hindsight and uncertain in the moment. Neurotech is at that moment now: brain-computer interfaces are in pivotal trials, neurostimulation is winning reimbursement, and neurological conditions are the world’s leading cause of illness and disability. Capital has not caught up to any of it. The investors who define this category will be the ones who backed it early, not the ones who arrived once it was consensus.
Target fund
Stage range
Geographic focus
Fund structure
Proof of execution
Proof of Execution
NeurotechMag Pro is live today, not a slide concept.
NeurotechMag Pro is the intelligence layer behind our sourcing and diligence, not a side project, a large part of why we believe we can find and win the right deals before the rest of the market catches on.
LP Benefits
- Co-investment access
- Invitations to the annual summit
- NeurotechMag Pro data access
- Early association with a category-defining Gulf neurotech platform
For select portfolio companies, we also help establish a GCC presence, extending their addressable market well beyond the initial check, and giving investors exposure to that regional growth.